Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 21, 2026
TickeronGET DAILY SIGNALS
10x Genomics (TXG) +35.7% in 30 Days: What Powered the Move

10x Genomics (TXG) +35.7% in 30 Days: What Powered the Move

Key Takeaways

  • 10x Genomics (TXG) shares climbed roughly 35.7% over the trailing 30 days, rising from a closing price of $47.05 to about $63.87.
  • The advance was powered by a stronger-than-expected Q2 2026 report, an upward revision to full-year revenue guidance, and early enthusiasm for the new Atera spatial biology platform.
  • Management raised its 2026 revenue outlook to $610–$630 million and pointed to AI-driven demand for biological data as a structural tailwind.
  • The broader quarter reflects a multi-month re-rating built on product innovation, the Proteintech Genomics acquisition, and high-profile research collaborations.

Company Overview and Market Position

10x Genomics designs and sells instruments, consumables, and software for analyzing biological systems at single-cell and spatial resolution. Its main platforms—Chromium for single-cell work and the Visium and Xenium spatial products—allow researchers to measure gene expression, epigenetics, and protein activity in large experiments. The company serves academic institutions, academic medical centers, and biopharmaceutical firms in the expanding single-cell and spatial biology segment. I keep an eye on TXG because of its recurring consumables revenue, leadership in high-resolution analysis, and exposure to AI applications in drug discovery and research. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Stock Price Performance Over the Last 30 Days and Quarter

Over the last 30 days, TXG moved from a closing price of $47.05 on July 22, 2026, to roughly $63.87, a gain of about $16.82 or approximately 35.7%. This marked a clear breakout after the stock had traded in the mid-to-high $40s for much of July. The quarterly view looks even stronger: as of early August, TXG had risen more than 110% over the trailing three months, extending a recovery from its 52-week low of $11.16. The multi-month uptrend points to improving demand fundamentals and a shift in sentiment toward life-science tools.

What Drove the Stock in the Last 30 Days

The main catalyst arrived in early August with second-quarter 2026 results that beat expectations. Revenue reached $151 million against a consensus estimate near $146.5 million, while the adjusted loss of $0.14 per share came in narrower than the roughly $0.24 loss analysts had projected. On a reported basis, revenue fell about 12.6% year over year, but excluding non-recurring settlement revenue it rose 3%. Management raised full-year 2026 revenue guidance to $610 million–$630 million from the prior $600 million–$625 million range. The higher outlook reflected strong early demand for Atera, the next-generation spatial whole-transcriptome platform. Booked Atera orders by quarter-end already exceeded the roughly 40 systems expected to ship in 2026, with manufacturing capacity rather than demand limiting shipments. The period also included the Proteintech Genomics acquisition, which expanded proteomics and multi-omics capabilities, plus a strategic research collaboration with the Cleveland Clinic. Gross margin improved to 74%, cash and marketable securities rose to about $552 million, and the company ended the quarter with no debt. These elements, along with growing attention on AI-driven biological research, supported the rally.

What Drove Performance Over the Last Quarter

The quarterly advance reflects a broader narrative shift. The Atera launch earlier in the year, unveiled at the AACR Annual Meeting 2026, positioned the company to expand its spatial biology opportunity and total addressable market. Early commitments from global service providers and AI-focused research programs added confidence in the platform’s potential. Underlying momentum includes improving academic funding dynamics after several challenging years, plus rising demand for high-quality single-cell and spatial data to train AI models. The Proteintech Genomics acquisition and Cleveland Clinic collaboration further broadened multi-omics and translational research reach, while the beat-and-raise report provided fresh evidence of improving fundamentals.

What to Watch Next for TXG

Several factors should shape the trajectory in coming quarters. The pace of Atera instrument shipments, heavily weighted toward the fourth quarter, will remain a focus, as will consumables pull-through once systems are installed. Management has signaled a modest sequential revenue decline in the third quarter as customers defer purchases of existing Xenium and Visium products ahead of the Atera transition. I’m watching the academic funding environment closely, along with competitive developments in spatial and single-cell biology. AI-related demand for large-scale biological datasets, adoption of the Flex Apex assay, and integration of Proteintech Genomics’ protein-analysis capabilities represent additional potential catalysts. Persistent operating losses and execution risk around manufacturing ramp-up remain the main considerations.

Using Tickeron’s Trending AI Robots

For traders looking for a systematic way to track momentum across thousands of equities, I often turn to Tickeron’s Trending AI Robots page. It provides a curated view of AI-driven trading bots that monitor thousands of tickers, featuring only the top-performing and most relevant ones. These bots cover different strategies, timeframes, and performance metrics, helping align tools with individual research and trading approaches.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TXG

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


TXG in downward trend: 10-day moving average broke below 50-day moving average on November 02, 2026

The 10-day moving average for TXG crossed bearishly below the 50-day moving average on November 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TXG as a result. In 69 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for TXG turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 35 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

TXG moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TXG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for TXG entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXG advanced for three days, in 212 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

TXG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.356) is normal, around the industry mean (4.142). P/E Ratio (-100.475) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (15.038) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -36%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 49
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a life science technology company, which engages in building products to interrogate, understand and master biology

Industry MedicalNursingServices

Industry
N/A
Address
6230 Stoneridge Mall Road
Phone
+1 925 401-7300
Employees
1178
Web
https://www.10xgenomics.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.